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An important new involvement of mesenchymal stem cells
(MSCs) in the complex scenario of atopic dermatitis (AD) is
addressed by Orciani et al. in the current issue of the BJD.1 In
the last decade, researchers have investigated deeply on possi-
ble MSC involvement in the onset of different diseases.2,3
Among different types of adult stem cells, MSCs have been
studied extensively and applied in several scientific and clinical
fields, including dermatology. MSCs are undifferentiated, mul-
tipotent and self-renewing cells that reside in many adult tis-
sues.4 They have several major characteristics including (i) the
ability of homing to areas of inflammation and tissue damage,
such as wounds or tumours;3 and (ii) the capacity to modu-
late innate and acquired immune responses.5 Interestingly,
Orciani et al.1 have previously hypothesized that the psoriatic
microenvironment may induce resident skin MSCs to produce
angiogenic and proinflammatory mediators, contributing to
the development of skin lesions.6,7 Moreover, it has been
shown by Liu et al. that MSCs obtained from psoriatic skin
lesions decreased the inhibitory effects on T-cell proliferation.8
An aberrant immune response, particularly by T cells, is also
typical of AD, which is characterized by a marked imbalance
of T-helper (Th)2 vs. Th1/Th17, especially in the early phase
whereas a mixed Th1/Th2 pattern is found at the chronic
stage.9 Phenotypic analysis of peripheral blood mononuclear
cells derived from patients with AD demonstrated a marked
increase in the interleukin (IL)-17+CD4+ T-cell population
compared with healthy controls. The highest percentage of IL-
17-producing cells was found in severe AD, suggesting a
direct correlation between the presence of Th17 cells and
severity of the disease.10,11 In their original article in the cur-
rent issue of the BJD, Orciani et al.1 convey their valuable expe-
rience with MSCs, evaluating whether a Th1/Th2 imbalance
could already be detected in undifferentiated cells of AD. They
have analysed the expression profile of 22 genes and proteins
related to Th1, Th2 and Th17 cytokines/chemokines in MSCs
from patients with AD (AD-MSCs) compared with healthy
controls (C-MSCs). They have shown that 14 of 22 genes
related to the Th1/Th17 pathway were upregulated whereas
three of 22 genes related to the Th2 pathway were downregu-
lated in AD-MSCs compared with C-MSCs. Moreover, they
showed in this paper that the profile of AD-MSCs retraces the
Th1/Th17 cell environment observed in differentiated cells of
chronic AD. Overall, the data from this manuscript provide
novel insights into AD pathogenesis, suggesting that the
inflammatory process detected in the MSCs has a determining
role in the typical Th1/Th2 imbalance. In summary, the find-
ings reported by Orciani et al.1 in the current issue of the BJD
have highlighted the current understanding of the interaction
between MSCs and the inflammatory response. Finally, we
would like to emphasize that although there is much evidence
supporting the effectiveness of MSCs in clinical dermatological
therapy, such as wound healing, it is important to underline
that the inflammatory microenvironment might also induce
transplanted MSCs to behave abnormally, modulating any pos-
sible beneficial effects. Future studies will need to elucidate the
role of stem cells in the control of inflammatory skin diseases.
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Interleukin (IL)-10 is an anti-inflammatory cytokine that sup-
presses production of cytokines in macrophages and modulates
antigen presentation by dendritic cells and suppresses costimula-
tory reactions by acting on T cells.1 IL-10 also plays an impor-
tant role in B-cell activation and in autoantibody production and
acts as an inhibitory factor during the production of T helper
cytokines.2 Recently, a specific subset of IL-10-producing regu-
latory B cells was identified as so-called B-10 cells and has been
shown to ameliorate imiquimod-induced, psoriasis-like skin
inflammation in a mouse model.3 Interestingly, the absolute
number of IL-10-producing regulatory B cells has been found to
be decreased in patients with psoriasis, while the number of
B-10 progenitor cells happened to be increased, implying that
there are abnormalities in the process of B-10 cell development
from B-10 progenitor cells in psoriasis.4 Moreover, it is well
known that psoriasis is characterized by a cutaneous IL-10
deficiency.5 Therefore, we may conclude that IL-10 is intricately
involved in the pathogenesis of psoriasis.
Interestingly, genome-wide association studies have failed so
far to identify IL-10 as a major genetic risk factor in contrast to
genes in the IL-23/T17 axis.6 Therefore, it is timely that Gal-
imova and her coworkers, in this issue of the BJD, report on
their extensive analysis of genetic polymorphisms in the IL-10
gene cluster on chromosome 1q31 with regard to psoriasis.7
They actually analysed 48 single-nucleotide polymorphisms of
the IL-10 gene cluster covering IL-10, IL-19, IL-20 and IL-24 in
a fairly large sample of 377 patients with psoriasis and 403 con-
trol individuals and identified a haplotype in the IL-10 gene that
conferred a protective effect. This effect even ‘survived’ a Bon-
ferroni correction for multiple testing and remained significant
(Pc = 0004). Even more interesting are their results of a two-
locus interaction between a marker in the IL-10 gene and a mar-
ker in the IL-20 gene. Although their study lacks a replication
cohort, which would have given further validation, their find-
ings are in line with a much earlier family-based association
study showing a protective effect of an allele in the IL-10 pro-
moter.8 Taken together, these two studies implicate members of
the IL-10 gene family as acting in a protective way against pso-
riasis. The question therefore arises: could IL-10 be a further
target to treat psoriasis in the future? In German, my answer
would be ‘Jein’ – meaning ‘yes and no’ at the same time. As a
matter of fact, recombinant IL-10 was tried already, 18 years
ago, as one of the first biologic agents in psoriasis9 and in the
meantime seven clinical trials have been conducted including
several phase II studies,5,10 but recombinant IL-10 as a biologic
has so far not found its way into clinical practice, probably
because other biologic agents are superior.
One limitation of biologic agents is that they do not reach
inside the cell to target intracellular signalling pathways, but
bind with receptors on extracellular membranes or extracellular
milieu.11 This approach apparently failed for IL-10. In contrast,
small drugs like the phosphodiesterase 4 inhibitor apremilast
can reach within the cell and by decreasing intracellular cAMP
increase, among others, the anti-inflammatory cytokine IL-
10.11 It is conceivable that similar small drugs may be devel-
oped in the future and that they may perhaps overcome the
blockade of IL-10-producing regulatory B cells from their B-10
progenitor cells. Thus, it is my feeling that IL-10 remains an
attractive, but certainly not easy, target in expanding our future
therapeutic armamentarium for the treatment of psoriasis.
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